TNFSF11 and metabolic dysfunction-associated steatotic liver disease: Bone formation inhibitors: NAFLD and fibrosis showed increased sclerostin levels (54.1 ± 16.4 vs. 36.1 ± 11.9 vs. 42.3 ± 14.7 pmol/L) and decreased serum DKK-1 (26.6 ± 17.8 vs. 49.0 ± 22.4 vs. 2.9 ± 19.4 pmol/L). Resorption markers: NAFLD and fibrosis group had decreased sCTX (0.16 ± 0.09 vs. 0.29 ± 0.17 vs. 0.40 ± 0.28 ng/mL) and increased RANKL (0.04 ± 0.03 vs. 0.08 ± 0.06 vs. 0.11 ± 0.06 pmol/L) compared to other groups.